KN046 in Patients With Advanced Non-small Cell Lung Cancer

NCT03838848 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

120

Enrollment

INDUSTRY

Sponsor class

Stopped Cohort A,B,C end enrollments. Cohort D and E were considered to have no significant clinical benefit at the SMC meeting and decided to terminate enrollment.

Conditions

Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: KN046
DRUG: KN046
DRUG: KN046
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Ningetinib

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd